We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





AITbiotech Exhibits abTES Molecular Diagnostics Assays at MEDLAB 2017

By LabMedica International staff writers
Posted on 09 Feb 2017
Print article
Image: The abTES Flu 4 qPCR VII test kit (Photo courtesy of AITbiotech).
Image: The abTES Flu 4 qPCR VII test kit (Photo courtesy of AITbiotech).
AITbiotech Pte Ltd., a Singapore-based genomic service and molecular diagnostics (MDx) company, exhibited its comprehensive range of abTES MDx assays, including its newly launched Zika assays and the multiplex respiratory panel, at MEDLAB 2017, the world’s largest laboratory exhibition and congress in the Middle East.

AITbiotech provides a complete suite of genomic services, including capillary sequencing, next-generation sequencing services, bioinformatics services and customized molecular services, to the research, healthcare and biomedical industries in Singapore and Asia. The company also manufactures and distributes its own line of real-time PCR pathogen detection assays branded as abTES in the Asian and European markets.

At MEDLAB 2017, held at the Dubai International Convention & Exhibition Centre, UAE, from February 6-9, 2017, AITbiotech showcased its abTES MDx range of assays, which uses real-time PCR (qPCR) technology to offer unsurpassed sensitivity and specificity, thus allowing for accurate detection of pathogens within hours. AITbiotech’s assays with internal control for simultaneous detection and differentiation of infectious pathogens are compatible with various platforms. Its timesaving and user-oriented protocols ensure fast turnaround time, from sample to results in 3.5 hours.

Alex Thian, CEO of AITbiotech, said, “We are excited to be part of this premier exhibition. After many years of development of our assays and focusing in the Asia Pacific market, we are finally are able to expand to more markets. We believe that Middle East will be the best market for us to expand into, primarily due to the relevance of our abTES assay offerings to the needs of the Middle East Market. We are looking for local partners to work with us collaboratively to introduce our abTES MDx assays to the Middle East market.”

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Gold Member
Chagas Disease Test
CHAGAS Cassette
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
Myeloperoxidase Assay
IDK MPO ELISA

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Pathology

view channel
Image: The study examined the influence of pre-analytical conditions on cell-free microRNA stability in blood plasma samples (Photo courtesy of 123RF)

Pre-Analytical Conditions Influence Cell-Free MicroRNA Stability in Blood Plasma Samples

Scientists worldwide are working to enhance the quality of diagnostics and prognosis for various diseases, including cancer, by analyzing different body fluids such as blood, urine, and saliva.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.